	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	R 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	R 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	139.69	147.91	178.87	187.16	202.48	228.91	211.48	225.01	171.09	250.53	281.21	304.22	339.22	303.08	311.66	334.41
Cost of Operating Revenue	85.35	83.00	99.97	106.23	111.79	122.72	108.05	123.43	91.47	160.47	176.57	181.90	201.82	167.66	158.33	176.20
Gross Profit	54.34	64.91	78.90	80.93	90.69	106.19	103.43	101.58	79.62	90.06	104.65	122.32	137.40	135.42	153.34	158.21
Gross Margin	38.9	43.9	44.1	43.2	44.8	46.4	48.9	45.1	46.5	35.9	37.2	40.2	40.5	44.7	49.2	47.3
Total Operating Expenses	128.72	135.51	165.73	177.07	194.64	220.59	201.19	213.66	174.01	235.59	266.78	288.22	317.76	283.29	-	311.96
Operating Profit	10.97	12.41	13.14	10.08	7.84	8.32	10.29	11.35	-2.92	14.94	14.44	15.99	21.46	19.79	-	22.45
Operating Margin	7.9	8.4	7.3	5.4	3.9	3.6	4.9	5.0	-1.7	6.0	5.1	5.3	6.3	6.5	-	6.7
Financing Income/(Expense) - Net	-7.48	-7.98	-7.16	-6.52	-6.48	-8.49	-9.14	-12.56	-12.45	-11.97	-10.41	-12.19	-15.26	-16.85	-16.82	-17.23
Profit before Taxes	4.37	5.09	6.63	4.74	2.65	2.87	2.88	-0.20	-13.53	4.10	9.18	4.75	9.05	5.14	5.93	6.86
Income Taxes	0.61	0.81	1.55	1.19	2.39	3.27	2.51	-2.36	-0.64	-0.61	3.48	2.13	1.60	-2.10	-0.39	-0.39
Profit after Tax	3.76	4.28	5.07	3.63	1.41	1.76	2.78	3.79	-12.22	4.74	5.61	2.57	7.39	7.22	-	7.21
PAT Margin	2.7	2.9	2.8	1.9	0.7	0.8	1.3	1.7	-7.1	1.9	2.0	0.8	2.2	2.4	-	2.2
EPS - Basic - ex Extraordinary Items	3.57	4.05	4.77	2.83	1.09	1.24	1.96	2.67	-8.62	3.34	3.71	1.64	4.68	4.55	-	4.54
EPS - Diluted - ex Extraordinary Items	3.57	4.05	4.60	2.80	1.09	1.24	1.96	2.67	-8.62	3.34	3.71	1.64	4.68	4.55	-	4.54
EBIT	10.97	12.41	13.14	10.08	7.84	8.32	10.29	11.35	-2.92	14.94	14.44	15.99	21.46	19.79	20.82	22.45
EBITDA	15.10	17.22	17.88	17.11	14.85	14.81	17.06	17.51	4.76	24.46	23.48	25.12	31.53	29.56	31.90	33.79
EBITDA Margin	10.8	11.6	10.0	9.1	7.3	6.5	8.1	7.8	2.8	9.8	8.3	8.3	9.3	9.8	10.2	10.1

Balance Sheet

Abridged

Understanding Balance Sheet

Bal Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31
	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	84.48	93.02	95.12	105.12	146.38	164.55	184.77	181.91	161.14	164.15	184.57	228.16	234.16	234.87	262.23
Long-Term Investments	0.01	0.01	0.01	0.01	0.55	0.34	0.56	2.55	1.56	2.49	1.95	3.50	2.67	7.13	8.07
Property Plant & Equipment - Net	47.67	47.62	50.56	48.09	55.39	57.02	63.37	64.48	63.77	57.51	57.19	62.18	64.79	73.78	84.18
Total Non-Current Assets	56.68	56.82	59.63	58.74	68.25	68.78	75.41	79.40	77.26	75.93	75.96	85.02	85.68	100.82	113.31
Total Assets	141.16	149.84	154.74	163.86	214.63	233.33	260.18	261.31	238.39	240.08	260.53	313.17	319.84	335.69	375.54
Total Current Liabilities	86.32	92.67	86.77	92.36	131.61	143.24	154.41	163.24	159.49	152.53	165.64	209.33	203.06	219.50	249.23
Long Term Debt	6.09	1.67	7.97	6.64	15.94	17.80	34.68	28.76	23.15	27.50	27.01	30.52	36.35	31.40	31.88
Total Non-Current Liabilities	14.79	12.55	17.92	16.34	26.55	30.02	45.57	37.85	33.56	34.19	36.40	40.14	44.81	38.79	44.06
Total Liabilities	101.11	105.22	104.69	108.70	158.16	173.26	199.98	201.09	193.06	186.73	202.04	249.47	247.87	258.29	293.29
Total Shareholders' Equity	40.06	44.62	50.05	55.20	56.70	62.45	64.99	66.64	52.43	53.58	58.63	63.79	72.00	77.42	82.23
Minority Interest	-	-	-	-0.03	-0.23	-2.38	-4.79	-6.42	-7.09	-0.23	-0.13	-0.09	-0.03	-0.01	0.03
Total Equity	40.06	44.62	50.05	55.17	56.47	60.07	60.20	60.22	45.34	53.35	58.49	63.70	71.97	77.40	-
Total Liabilities & Equity	141.16	149.84	154.74	163.86	214.63	233.33	260.18	261.31	238.39	240.08	260.53	313.17	319.84	335.69	-

Cash Flow

Abridged

Understanding Cash Flow Statement

Bal Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	C 2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	C 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	C 2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	6.80	7.49	8.91	8.90	7.14	7.96	7.73	3.01	-6.66	13.80	14.91	12.44	11.21	11.69	32.47
Working Capital - Increase/(Decrease)	-1.05	0.87	-2.59	-0.59	-32.66	-9.95	-16.18	-7.07	17.94	-3.35	1.66	-27.52	-4.04	-7.49	-1.64
Net CF from Operating Activities	5.76	8.36	6.32	8.31	-25.53	-1.99	-8.45	-4.06	11.28	10.45	16.57	-15.08	7.17	4.20	14.86
Capital Expenditures - Net	2.51	4.21	7.46	5.59	14.19	8.14	3.78	8.58	5.04	3.39	8.47	14.65	10.97	18.79	22.32
Net CF from Investing Activities	-2.42	-4.21	-7.46	-5.59	-14.19	-8.14	-3.78	-8.58	-5.04	-5.25	-9.66	-22.32	-19.58	-15.65	-21.54
Dividends Paid - Cash - Total	-	-	0.93	1.51	1.52	1.68	1.68	1.47	1.42	-	1.48	1.56	1.57	1.91	1.91
Stock - Issuance/(Retirement) - Net	-	1.21	1.66	3.98	20.00	8.06	-	-	-	0.94	-	3.44	1.23	0.81	-
Debt - LT & ST - Issuance/(Retirement) - Total	-2.42	-3.85	-1.10	-2.76	20.37	-3.83	14.46	13.83	-6.25	-8.92	-6.25	35.42	16.19	10.78	9.14
Net Cash Flow from Financing Activities	-2.28	-2.64	-0.37	-0.29	38.85	2.55	12.78	12.36	-7.67	-5.03	-6.82	37.78	15.12	9.01	7.23
Free Cash Flow to Equity	0.83	0.30	-2.24	-0.04	-19.34	-13.96	2.23	1.20	-0.02	-1.87	1.85	5.69	12.39	-3.81	1.68
Free Operating CF net dividend	2.12	4.09	-2.07	1.18	-41.25	-11.83	-13.91	-14.12	4.80	7.04	6.62	-31.28	-5.38	-16.50	-9.43
Free Operating CF	2.12	4.09	-1.14	2.69	-39.73	-10.14	-12.23	-12.65	6.21	7.04	8.10	-29.73	-3.81	-14.59	-7.52

Business Segment Analysis

Bal Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

We don't have enough data to show business segment analysis for Bal Pharma Ltd.

Regional Segment Analysis

FY End:

Mar 13

Bal Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Other than India (58.7%)₹ 86.04 CrIndia (41.3%)₹ 60.55 Cr

Historical Segment Analysis

Track how Bal Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Sales

Business

Regional

Business

We don't have enough data to show the Capex for Bal Pharma Ltd..

Frequently Asked Questions

What is the revenue of Bal Pharma Ltd.?

The latest trailing twelve month revenue of Bal Pharma Ltd. is ₹ 334.85 Cr, reflecting a 1-year growth of 13.66% and a 3-year CAGR of 3.19%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Bal Pharma Ltd.?

The latest trailing twelve month net profit (PAT) of Bal Pharma Ltd. is ₹ 6.08 Cr, with a 3-year earnings CAGR of 46.67%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Bal Pharma Ltd.?

The trailing twelve month EBITDA of Bal Pharma Ltd. is approximately ₹ 22.37 Cr (based on an operating margin of 6.68%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Bal Pharma Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Bal Pharma Ltd. is 4.54. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Bal Pharma Ltd.?

The debt-to-equity ratio of Bal Pharma Ltd. stands at 1.94. The interest coverage ratio is 1.30x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Bal Pharma Ltd.?

The estimated book value per share of Bal Pharma Ltd. is 51.65 (derived from a P/B ratio of 1.62 and market price of ₹ 83.57), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Bal Pharma Ltd.?

The trailing twelve month operating cash flow of Bal Pharma Ltd. is ₹ 14.47 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Bal Pharma Ltd. report consolidated or standalone financials?

Bal Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.